![Kymera Therapeutics, Inc. logo](/logos/KYMR.webp)
Kymera Therapeutics, Inc.
NASDAQ:KYMR
Overview | Financials
Company Name | Kymera Therapeutics, Inc. |
Symbol | KYMR |
Currency | USD |
Price | 45.4 |
Market Cap | 2,894,504,240 |
Dividend Yield | 0% |
52-week-range | 9.6 - 50.185 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Nello Mainolfi M.D., Ph.D. |
Website | https://www.kymeratx.com |
An error occurred while fetching data.
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD